rev beat ep beat exclud benefit
late gener rebat adjust perform
mainli in-lin consensu management rais revenu guidanc
in-line beat ceo day long-term vision remain
key driver expect limit movement
non-gaap ep beat higher revenu non-gaap ep
vs con sever product consensu includ atripla
truvada genvoya descovi odefsey
howev product off-set biktarvi epclusa
letairi yescarta perform loos line
expect vs con management note revenu quarter
benefit due adjust rebat relat prior year sale
europ benefit split across hiv hcv hbv
normal benefit hiv miss hcv beat
overal beat without item vs con
mainli driven higher letairi expect erod management increas
sale guidanc leav guidanc
gross margin expens sg expens
tax rate unchang new estim high-end
management rang
takeaway call hiv capsid inhibitor
initi data present recent aid societi
confer management plan discuss regulatori next step fda
come week management expect use combin
intern agent detail potenti combin made avail
next month management also believ could eventu
use prep agent management note regulatori file filgotinib ra
eu immin reiter nda submit fda
management note gilead open consid busi develop
opportun across varieti structur focu current area
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
expertis includ hiv oncolog liver diseas inflamm
patient take truvada prep management estim repres
prep elig popul descovi prep file
 approv anticip note adcom schedul
file eu expect management note medicar
part account low double-digit percentag compani sale
current yescarta author center across
quarter mix long-term vision compani remain
key driver despit top-line beat quarter larg driven
item unlik repeat limit enthusiasm
number said biktarvi perform remain impress
rais long-term number off-set faster declin hiv
product believ investor remain focus new ceo day plan
reshap compani come month particular focu fall
strateg plan outsid busi develop next key catalyst
remain file filgotinib ra fda decis
snda descovi prep adcom held given line
perform signific catalyst updat expect minim
movement base quarter
current act financi advisor galapago
galapago relat agreement enter global
collabor inc cover galapago current futur
portfolio collabor announc juli propos
transact subject requir regulatori approv customari close
condit certain element collabor subject approv
galapago sharehold galapago agre pay fee morgan stanley
servic conting upon consumm propos
transact pleas refer note end report
durat hcv sale hiv patent expir car-t/pipelin drive risk-reward
durat hcv sale hiv patent expir car-t/pipelin drive risk-reward
less rapid eros hcv franchis strong pipelin realiz drive bull
case hiv product revenu reach hcv busi gener
sale ww sale yescarta filgotinib
gilead respect
rapid hcv eros lower pipelin success bull case hiv
product revenu reach hcv busi declin sale
ww sale yescarta filgotinib
gilead respect
stabl hiv revenu quick hcv busi eros minim pipelin
success hiv product revenu hcv busi gener
sale littl pipelin valu
equal-weight gilead believ
offer signific absolut
upsid near-term catalyst
term upsid rel gilead
signific return capit share
repurchas low forward price-to-earnings multipl
offer downsid protect
believ hcv peak us
continu declin modestli
howev believ cash flow gener
robust
hiv gilead done good job
switch nave patient new
stribild complera genvoya
truvada/atripla still hold market
right mean signific number
still need switch howev given time
solid taf switch data believ
least half market switch
gilead partnership galapago
acquisit kite provid potenti
main driver hiv franchis
galapago partnership hcv franchis
car-t franchis pipelin capit
deploy repres key driver
risk achiev price
unexpect competit hiv
rapid hcv eros
appreci consensu
failur car-t achiev signific
market penetr failur meaning
royalti contract revenu
net loss non-controlling interest
net incom gilead non-gaap
revenu share symtuza us
revenu share symtuza europ
total hiv hcv start
hcv exclud sovaldi start
royalti contract revenu
contract revenu
equival
non-curr portion prepaid royalti
current portion long term debt
total liabil equiti
in-process research develop impair charg
tax benefit relat employe stock option
amort bond discount
chang oper asset liabil
accru liabil tax payabl
net cash provid use oper activ
purchas pp
net cash use invest activ
flow financ activ
proce issuanc common stock eso
excess tax benefit stock-bas compens
proce sale of/ payment settl warrant
proceeds/ purchas convert note hedg
proce from/ repay debt financ
contribut distribut non-controlling interest
repurchas common stock
net cash provid financ activ
effect exchang rate chang
chang cash
begin year
end year
